Target ESR2 for Therapeutic Cancer Treatments (G2100)

Target Name: ESR2

NCBI ID: G2100

ESR2

Target ESR2 for Therapeutic Cancer Treatments

Estrogen receptor beta (ESR2) is a protein that plays a crucial role in the regulation of various physiological processes in the body. It is a key regulator of cell growth, differentiation, and adhesion, and is involved in the development and maintenance of tissues such as breast, uterine, and prostate cells. ESR2 has also been shown to be involved in the regulation of various signaling pathways, including the TGF-β pathway.

Drugs that target ESR2 have the potential to treat a variety of diseases, including breast cancer, uterine cancer, and prostate cancer. These drugs work by inhibiting the activity of ESR2, which can lead to the growth or division of cancer cells that have the potential to form tumors.

Targeting ESR2

ESR2 is a protein that is expressed in a wide range of tissues and cells in the body. It is primarily localized to the nuclear envelope of cells, where it is involved in regulating various cellular processes. ESR2 is a nuclear protein, which means that it is primarily localized to the nucleus of the cell.

ESR2 is a member of the estrogen receptor family, which includes several other proteins that are involved in the regulation of estrogen signaling. These proteins include estrogen receptor alpha (ER伪), estrogen receptor delta (ER未), and estrogen receptor gamma (ERG).

ESR2 is involved in the regulation of various cellular processes, including cell growth, differentiation, and adhesion. It is also involved in the development and maintenance of tissues such as breast, uterine, and prostate cells.

ESR2 has been shown to play a key role in the regulation of the TGF-β pathway, which is a signaling pathway that is involved in the development and maintenance of tissues. The TGF-β pathway is a critical regulator of cell growth, differentiation, and adhesion, and is involved in the development and maintenance of tissues such as breast, uterine, and prostate cells.

ESR2 is also involved in the regulation of the Wnt signaling pathway, which is a signaling pathway that is involved in the development and maintenance of tissues. The Wnt signaling pathway is a critical regulator of cell growth, differentiation, and adhesion, and is involved in the development and maintenance of tissues such as neural tube, heart, and limb bud.

Drugs that target ESR2

Drugs that target ESR2 have the potential to treat a variety of diseases, including breast cancer, uterine cancer, and prostate cancer. These drugs work by inhibiting the activity of ESR2, which can lead to the growth or division of cancer cells that have the potential to form tumors.

One of the main classes of drugs that target ESR2 is called Selective Estrogen Receptor Modulators (SERMs). These drugs work by inhibiting the activity of ESR2, which can lead to the growth or division of cancer cells that have the potential to form tumors.

SERMs are commonly used to treat breast and uterine cancers. They work by inhibiting the activity of ESR2, which can lead to the growth or division of cancer cells that have the potential to form tumors.

Another class of drugs that target ESR2 is called Phosphatidylinositol inhibitors. These drugs work by inhibiting the activity of ESR2, which can lead to the growth or division of cancer cells that have the potential to form tumors.

Phosphatidylinositol inhibitors are commonly used to treat breast and uterine cancers. They work by inhibiting the activity of ESR2, which can lead to the growth or division of cancer cells that have the potential to form tumors.

Other classes of drugs that target ESR2 include Small Molecule inhibitors, such as letrozole and anastrozole, which are commonly used to treat breast cancer. These drugs work by inhibiting the activity of

Protein Name: Estrogen Receptor 2

Functions: Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560)

The "ESR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ESR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets